BR112023006497A2 - Polipeptídios direcionados para sars-cov-2 e composições e métodos relacionados - Google Patents

Polipeptídios direcionados para sars-cov-2 e composições e métodos relacionados

Info

Publication number
BR112023006497A2
BR112023006497A2 BR112023006497A BR112023006497A BR112023006497A2 BR 112023006497 A2 BR112023006497 A2 BR 112023006497A2 BR 112023006497 A BR112023006497 A BR 112023006497A BR 112023006497 A BR112023006497 A BR 112023006497A BR 112023006497 A2 BR112023006497 A2 BR 112023006497A2
Authority
BR
Brazil
Prior art keywords
cov
sars
methods
nanocage
related compositions
Prior art date
Application number
BR112023006497A
Other languages
English (en)
Portuguese (pt)
Inventor
Rujas Diez Edurne
Jean-Philippe Julien
Original Assignee
Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital For Sick Children filed Critical Hospital For Sick Children
Publication of BR112023006497A2 publication Critical patent/BR112023006497A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
BR112023006497A 2020-10-09 2021-10-08 Polipeptídios direcionados para sars-cov-2 e composições e métodos relacionados BR112023006497A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063089782P 2020-10-09 2020-10-09
US202163197236P 2021-06-04 2021-06-04
US202163220929P 2021-07-12 2021-07-12
PCT/CA2021/051426 WO2022073138A1 (en) 2020-10-09 2021-10-08 Polypeptides targeting sars-cov-2 and related compositions and methods

Publications (1)

Publication Number Publication Date
BR112023006497A2 true BR112023006497A2 (pt) 2023-11-21

Family

ID=81126329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006497A BR112023006497A2 (pt) 2020-10-09 2021-10-08 Polipeptídios direcionados para sars-cov-2 e composições e métodos relacionados

Country Status (9)

Country Link
US (1) US20250263469A1 (https=)
EP (1) EP4225804A4 (https=)
JP (1) JP2023544211A (https=)
KR (1) KR20230083316A (https=)
AU (1) AU2021356355A1 (https=)
BR (1) BR112023006497A2 (https=)
CA (1) CA3197642A1 (https=)
MX (1) MX2023004023A (https=)
WO (1) WO2022073138A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法
US20250276070A1 (en) * 2021-07-12 2025-09-04 The Hospital For Sick Children Optimized multabody constructs, compositions, and methods
KR102946895B1 (ko) 2022-10-21 2026-04-02 충남대학교산학협력단 SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도
JP2025536337A (ja) * 2022-10-21 2025-11-05 ザ・ホスピタル・フォー・シック・チルドレン サルベコウイルスを標的とするマルタボディ構築物、組成物および方法
WO2025231346A1 (en) * 2024-05-03 2025-11-06 The Wistar Institute Of Anatomy And Biology Anti-interferon-alpha and anti-interferon-beta antibodies, and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
KR20150037959A (ko) * 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
BR112019001262A2 (pt) * 2016-07-22 2019-05-07 Dana-Farber Cancer Institute, Inc. anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN111592595B (zh) * 2020-04-27 2021-02-19 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用

Also Published As

Publication number Publication date
EP4225804A4 (en) 2025-07-02
JP2023544211A (ja) 2023-10-20
AU2021356355A1 (en) 2023-05-25
WO2022073138A1 (en) 2022-04-14
EP4225804A1 (en) 2023-08-16
KR20230083316A (ko) 2023-06-09
MX2023004023A (es) 2023-07-07
US20250263469A1 (en) 2025-08-21
CA3197642A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
BR112023006497A2 (pt) Polipeptídios direcionados para sars-cov-2 e composições e métodos relacionados
Leivo et al. Merosin, a protein specific for basement membranes of Schwann cells, striated muscle, and trophoblast, is expressed late in nerve and muscle development.
Chiquet-Ehrismann et al. Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues.
Handa et al. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments.
Tenbroek et al. The distribution of the fiber cell intrinsic membrane proteins MP20 and connexin46 in the bovine lens
Lehtonen et al. Parietal and visceral endoderm differ in their expression of intermediate filaments.
Kobayashi et al. Isolation and characterization of a new 36-kDa microfibril-associated glycoprotein from porcine aorta
PE20090322A1 (es) Fraccion de anticuerpo y anticuerpo antagonista del factor de crecimiento endotelial vascular
TW201304802A (zh) 調節細胞激素活性之方法及相關藥劑
CO2023014734A2 (es) Polipéptidos de unión a antígeno bma031 mejorados
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
Lee et al. Structural similarities and differences between neurofilament proteins from five different species as revealed using monoclonal antibodies
Smales et al. Occludin phosphorylation: identification of an occludin kinase in brain and cell extracts as CK2
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
JP2021506310A5 (https=)
Trummal et al. Molecular diversity of snake venom nerve growth factors
WO2022162012A3 (en) Antibodies broadly targeting coronaviruses and uses thereof
Dehan et al. Sera from patients with anti-GBM nephritis including Goodpasture syndrome show heterogenous reactivity to recombinant NC1 domain of type IV collagen α chains
Ku et al. Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma‐associated antigen HAb18G/CD147
Aizawa et al. Limited chymotryptic digestion of bovine adrenal 190,000-Mr microtubule-associated protein and preparation of a 27,000-Mr fragment which stimulates microtubule assembly.
Ewins et al. Mapping epitope specificities of monoclonal antibodies to thyroid peroxidase using recombinant antigen preparations
O'Halloran et al. Purification of a 190 kDa protein from smooth muscle: relationship to talin
Redmond et al. Interspecies conservation of structure of interphotoreceptor retinoid-binding protein Similarities and differences as adjudged by peptide mapping and N-terminal sequencing
Kefalides et al. Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen
Imamura et al. A novel nonmuscle alpha-actinin. Purification and characterization of chicken lung alpha-actinin.